上皮性卵巣がんの世界市場レポート 2025年

上皮性卵巣がん市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR16.1％で44億1,000万米ドルに成長します。予測期間においては、卵巣がんの罹患率の増加、人口の高齢化、卵巣がんに対する意識の高まり、がんに対する研究資金の増加、がん撲滅を目的とした政府のイニシアチブの高まりなどにより成長が見込まれます。この期間の主な動向としては、医療用画像の技術的進歩、新しい分子診断ツールの導入、製薬企業間の協働、診断におけるAIと機械学習の急速な導入、ロボット手術の利用の拡大などが挙げられます。

卵巣がんの罹患率の増加は、今後数年間の上皮性卵巣がん市場の拡大を牽引すると予想されます。卵巣がんは卵巣から始まり、主に卵巣表面を覆う上皮細胞を侵します。この有病率の増加は、人口の高齢化、認知度の向上、発見率の改善、遺伝やライフスタイルなどの要因によるところが大きいです。上皮性卵巣がんの治療は、この一般的で侵攻性の強い病態に対処するために不可欠であり、悪性細胞を標的とすることで生存率と患者の予後を向上させる。カナダに本部を置く非営利団体World Ovarian Cancer Coalitionによると、卵巣がんと診断される女性の数は、2050年までに世界で55％以上増加し、50万3,448人に達すると予測されています。さらに、卵巣がんによる年間死亡者数は2022年から70％近く増加し、35万956人に達すると予想されています。その結果、卵巣がんの有病率の増加が上皮性卵巣がん治療市場を促進することになります。

上皮性卵巣がん市場の主要企業は、がん細胞で過剰発現した葉酸受容体αを標的とするFRa指向性抗体薬物複合体（ADC）などの最先端の治療ソリューションの開発に注力しています。これらの治療法は、健康な組織へのダメージを最小限に抑えながら、強力な細胞傷害性薬剤をがん細胞に直接送達します。例えば、米国に本社を置くバイオ医薬品会社アッヴィ社は、2024年11月、欧州委員会からELAHERE（mirvetuximab soravtansine）の承認を取得しました。この標的療法は、FRa陽性でプラチナ製剤抵抗性の高悪性度漿液性上皮性卵巣がん、卵管がん、原発性腹膜がんの成人患者を対象としています。エラヒールは、過去に3回までの全身療法を受けた患者に対して有効な治療選択肢を提供します。卵巣がん患者の約3分の1に存在するバイオマーカーを標的とすることで、生存の見込みを改善し、患者のQOLを向上させる。今回の承認には、対象となる患者を特定するためのコンパニオン診断薬も含まれます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界上皮性卵巣がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の上皮性卵巣がん市場：成長率分析
• 世界の上皮性卵巣がん市場の実績：規模と成長, 2019-2024
• 世界の上皮性卵巣がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界上皮性卵巣がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の上皮性卵巣がん市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的療法
• 免疫療法
• ホルモン療法
• 手術
• 世界の上皮性卵巣がん市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プラチナ製剤化学療法薬
• ポリ（ADP-リボース）ポリメラーゼ阻害剤
• ベバシズマブ
• 化学療法剤
• 世界の上皮性卵巣がん市場がんのステージ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 早期
• 上級段階
• 世界の上皮性卵巣がん市場診断方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 画像診断
• 生検
• 血液検査
• 世界の上皮性卵巣がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 診断検査室
• 世界の上皮性卵巣がん市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プラチナ製剤化学療法
• 非プラチナ化学療法
• 併用化学療法
• 世界の上皮性卵巣がん市場標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• PARP阻害剤
• 血管新生阻害剤
• その他の標的エージェント
• 世界の上皮性卵巣がん市場免疫療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• チェックポイント阻害剤
• がんワクチン
• 養子T細胞療法
• 世界の上皮性卵巣がん市場ホルモン療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的エストロゲン受容体モジュレーター（SERM）
• アロマターゼ阻害剤
• プロゲスチン
• 世界の上皮性卵巣がん市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 減量手術
• 卵巣摘出術
• 子宮摘出術
• その他の外科手術

第7章 地域別・国別分析

• 世界の上皮性卵巣がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の上皮性卵巣がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 上皮性卵巣がん市場：競合情勢
• 上皮性卵巣がん市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline plc
• Eli Lilly and Company
• Boehringer Ingelheim GmbH
• Merck KGaA
• Siemens Healthineers AG
• Quest Diagnostics Incorporated
• Eisai Co. Ltd.
• Genentech Inc.
• Qiagen N.V.
• Myriad Genetics Inc.
• Zymeworks Inc.
• Novogen Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 上皮性卵巣がん市場2029：新たな機会を提供する国
• 上皮性卵巣がん市場2029：新たな機会を提供するセグメント
• 上皮性卵巣がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Epithelial ovarian cancer (EOC) is the most common form of ovarian cancer, originating from the epithelial cells that make up the outer layer of the ovary. It typically affects women over the age of fifty and is often asymptomatic in the early stages, resulting in late-stage diagnoses when the cancer has already progressed. When symptoms do appear, they may include abdominal bloating, pelvic pain, frequent urination, and changes in bowel movements.

The main treatment options for epithelial ovarian cancer include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and surgery. Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells, with options such as platinum-based drugs, poly(adp-ribose) polymerase inhibitors, bevacizumab, and other chemotherapeutic agents. Chemotherapy is used in both early and advanced stages of the disease. Diagnosis can be made through imaging, biopsies, and blood tests, and the treatment is commonly administered in hospitals, clinics, and diagnostic laboratories.

The epithelial ovarian cancer market research report is one of a series of new reports from The Business Research Company that provides epithelial ovarian cancer market statistics, including epithelial ovarian cancer industry global market size, regional shares, competitors with a epithelial ovarian cancer market share, detailed epithelial ovarian cancer market segments, market trends and opportunities, and any further data you may need to thrive in the epithelial ovarian cancer industry. This epithelial ovarian cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epithelial ovarian cancer market size has grown rapidly in recent years. It will grow from $2.08 billion in 2024 to $2.42 billion in 2025 at a compound annual growth rate (CAGR) of 16.5%. The growth during the historical period can be attributed to factors such as the increasing demand for personalized cancer treatments, rising global healthcare spending, a growing preference for minimally invasive surgeries, a higher number of ovarian cancer survivors, increased demand for gene therapies, and a rise in the need for palliative care services.

The epithelial ovarian cancer market size is expected to see rapid growth in the next few years. It will grow to $4.41 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. In the forecast period, growth is expected due to the increasing incidence of ovarian cancer, an aging population, greater awareness of ovarian cancer, more research funding for cancer, and growing government initiatives aimed at combating cancer. Key trends during this period include technological advancements in medical imaging, the introduction of new molecular diagnostic tools, collaborations between pharmaceutical companies, the rapid adoption of AI and machine learning in diagnostics, and a growing use of robotic surgeries.

The growing incidence of ovarian cancer is expected to drive the expansion of the epithelial ovarian cancer market in the coming years. Ovarian cancer begins in the ovaries, primarily affecting the epithelial cells that line their surface. This increase in prevalence is largely attributed to an aging population, better awareness, improved detection rates, and factors such as genetics and lifestyle. Treatment for epithelial ovarian cancer is essential in addressing this common and aggressive form of the disease, targeting malignant cells to enhance survival and patient outcomes. According to the World Ovarian Cancer Coalition, a non-profit organization based in Canada, the global number of women diagnosed with ovarian cancer is projected to rise by over 55% by 2050, reaching 503,448. Additionally, annual deaths from ovarian cancer are expected to increase by nearly 70% from 2022, reaching 350,956. As a result, the growing prevalence of ovarian cancer will propel the market for epithelial ovarian cancer treatments.

Leading companies in the epithelial ovarian cancer market are focusing on developing cutting-edge treatment solutions, such as FRa-directed antibody-drug conjugates (ADCs), which target the folate receptor-alpha overexpressed on cancer cells. These treatments deliver potent cytotoxic agents directly to the cancer cells, while minimizing damage to healthy tissues. For example, in November 2024, AbbVie Inc., a biopharmaceutical company based in the United States, received European Commission approval for ELAHERE (mirvetuximab soravtansine). This targeted therapy is designed for adult patients with FRa-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE offers an effective treatment option for patients who have undergone up to three prior systemic regimens. By targeting a biomarker present in about one-third of ovarian cancer patients, it improves survival prospects and enhances the patient's quality of life. The approval also includes a companion diagnostic to help identify eligible patients.

In February 2024, AbbVie Inc. acquired ImmunoGen in a deal worth $10.1 billion to expand its oncology portfolio. This acquisition brings ELAHERE, a targeted antibody-drug conjugate for treating platinum-resistant ovarian cancer, into AbbVie's offerings. The move aims to reduce reliance on older drugs and position AbbVie within the growing ADC market. ImmunoGen, a US-based manufacturer, specializes in drugs for epithelial ovarian cancer.

Major players in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Zymeworks Inc., Novogen Limited, Karyopharm Therapeutics Inc., Clovis Oncology Inc., ImmunoGen Inc., Fujirebio Diagnostics Inc., and Vivesto AB.

North America was the largest region in the epithelial ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in epithelial ovarian cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the epithelial ovarian cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The epithelial ovarian cancer market consists of revenues earned by entities by providing services such as genetic testing, supportive care services, telemedicine, and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The epithelial ovarian cancer market also includes sales of diagnostic kits, targeted therapy drugs, chemotherapeutic agents, surgical instruments, and devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Epithelial Ovarian Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on epithelial ovarian cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for epithelial ovarian cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The epithelial ovarian cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Treatment: Chemotherapy; Targeted Therapy; Immunotherapy; Hormonal Therapy; Surgery
• 2) By Drug Class: Platinum-based Chemotherapy Drugs; Poly(ADP-ribose) Polymerase Inhibitors; Bevacizumab; Chemotherapeutic Agents
• 3) By Stage Of Cancer: Early Stage; Advanced Stage
• 4) By Diagnosis Method: Imaging; Biopsy; Blood Tests
• 5) By End User: Hospitals; Clinics; Diagnostic Laboratories
• Subsegments:
• 1) By Chemotherapy: Platinum-Based Chemotherapy; Non-Platinum Chemotherapy; Combination Chemotherapy
• 2) By Targeted Therapy: Monoclonal Antibodies; PARP Inhibitors; Angiogenesis Inhibitors; Other Targeted Agents
• 3) By Immunotherapy: Checkpoint Inhibitors; Cancer Vaccines; Adoptive T-Cell Therapy
• 4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Progestins
• 5) By Surgery: Debulking Surgery; Oophorectomy; Hysterectomy; Other Surgical Procedures
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Epithelial Ovarian Cancer Market Characteristics

3. Epithelial Ovarian Cancer Market Trends And Strategies

4. Epithelial Ovarian Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Epithelial Ovarian Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Epithelial Ovarian Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Epithelial Ovarian Cancer Market Growth Rate Analysis
• 5.4. Global Epithelial Ovarian Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Epithelial Ovarian Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Epithelial Ovarian Cancer Total Addressable Market (TAM)

6. Epithelial Ovarian Cancer Market Segmentation

• 6.1. Global Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy
• Surgery
• 6.2. Global Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Platinum-based Chemotherapy Drugs
• Poly(ADP-ribose) Polymerase Inhibitors
• Bevacizumab
• Chemotherapeutic Agents
• 6.3. Global Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early Stage
• Advanced Stage
• 6.4. Global Epithelial Ovarian Cancer Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging
• Biopsy
• Blood Tests
• 6.5. Global Epithelial Ovarian Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Diagnostic Laboratories
• 6.6. Global Epithelial Ovarian Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Platinum-Based Chemotherapy
• Non-Platinum Chemotherapy
• Combination Chemotherapy
• 6.7. Global Epithelial Ovarian Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• PARP Inhibitors
• Angiogenesis Inhibitors
• Other Targeted Agents
• 6.8. Global Epithelial Ovarian Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitors
• Cancer Vaccines
• Adoptive T-Cell Therapy
• 6.9. Global Epithelial Ovarian Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Estrogen Receptor Modulators (SERMs)
• Aromatase Inhibitors
• Progestins
• 6.10. Global Epithelial Ovarian Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Debulking Surgery
• Oophorectomy
• Hysterectomy
• Other Surgical Procedures

7. Epithelial Ovarian Cancer Market Regional And Country Analysis

• 7.1. Global Epithelial Ovarian Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Epithelial Ovarian Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Epithelial Ovarian Cancer Market

• 8.1. Asia-Pacific Epithelial Ovarian Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Epithelial Ovarian Cancer Market

• 9.1. China Epithelial Ovarian Cancer Market Overview
• 9.2. China Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Epithelial Ovarian Cancer Market

• 10.1. India Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Epithelial Ovarian Cancer Market

• 11.1. Japan Epithelial Ovarian Cancer Market Overview
• 11.2. Japan Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Epithelial Ovarian Cancer Market

• 12.1. Australia Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Epithelial Ovarian Cancer Market

• 13.1. Indonesia Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Epithelial Ovarian Cancer Market

• 14.1. South Korea Epithelial Ovarian Cancer Market Overview
• 14.2. South Korea Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Epithelial Ovarian Cancer Market

• 15.1. Western Europe Epithelial Ovarian Cancer Market Overview
• 15.2. Western Europe Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Epithelial Ovarian Cancer Market

• 16.1. UK Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Epithelial Ovarian Cancer Market

• 17.1. Germany Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Epithelial Ovarian Cancer Market

• 18.1. France Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Epithelial Ovarian Cancer Market

• 19.1. Italy Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Epithelial Ovarian Cancer Market

• 20.1. Spain Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Epithelial Ovarian Cancer Market

• 21.1. Eastern Europe Epithelial Ovarian Cancer Market Overview
• 21.2. Eastern Europe Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Epithelial Ovarian Cancer Market

• 22.1. Russia Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Epithelial Ovarian Cancer Market

• 23.1. North America Epithelial Ovarian Cancer Market Overview
• 23.2. North America Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Epithelial Ovarian Cancer Market

• 24.1. USA Epithelial Ovarian Cancer Market Overview
• 24.2. USA Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Epithelial Ovarian Cancer Market

• 25.1. Canada Epithelial Ovarian Cancer Market Overview
• 25.2. Canada Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Epithelial Ovarian Cancer Market

• 26.1. South America Epithelial Ovarian Cancer Market Overview
• 26.2. South America Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Epithelial Ovarian Cancer Market

• 27.1. Brazil Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Epithelial Ovarian Cancer Market

• 28.1. Middle East Epithelial Ovarian Cancer Market Overview
• 28.2. Middle East Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Epithelial Ovarian Cancer Market

• 29.1. Africa Epithelial Ovarian Cancer Market Overview
• 29.2. Africa Epithelial Ovarian Cancer Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Epithelial Ovarian Cancer Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Epithelial Ovarian Cancer Market, Segmentation By Stage Of Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Epithelial Ovarian Cancer Market Competitive Landscape And Company Profiles

• 30.1. Epithelial Ovarian Cancer Market Competitive Landscape
• 30.2. Epithelial Ovarian Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Epithelial Ovarian Cancer Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca PLC
• 31.4. GlaxoSmithKline plc
• 31.5. Eli Lilly and Company
• 31.6. Boehringer Ingelheim GmbH
• 31.7. Merck KGaA
• 31.8. Siemens Healthineers AG
• 31.9. Quest Diagnostics Incorporated
• 31.10. Eisai Co. Ltd.
• 31.11. Genentech Inc.
• 31.12. Qiagen N.V.
• 31.13. Myriad Genetics Inc.
• 31.14. Zymeworks Inc.
• 31.15. Novogen Limited

32. Global Epithelial Ovarian Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Epithelial Ovarian Cancer Market

34. Recent Developments In The Epithelial Ovarian Cancer Market

35. Epithelial Ovarian Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Epithelial Ovarian Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Epithelial Ovarian Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Epithelial Ovarian Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer